ES2132063T3 - Procedimiento para la captura y recuperacion de celulas. - Google Patents

Procedimiento para la captura y recuperacion de celulas.

Info

Publication number
ES2132063T3
ES2132063T3 ES90307080T ES90307080T ES2132063T3 ES 2132063 T3 ES2132063 T3 ES 2132063T3 ES 90307080 T ES90307080 T ES 90307080T ES 90307080 T ES90307080 T ES 90307080T ES 2132063 T3 ES2132063 T3 ES 2132063T3
Authority
ES
Spain
Prior art keywords
cells
separation
suspensions
interest
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90307080T
Other languages
English (en)
Inventor
Thomas B Okarma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Rorer Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer Pharmaceutical Products Inc filed Critical Rorer Pharmaceutical Products Inc
Application granted granted Critical
Publication of ES2132063T3 publication Critical patent/ES2132063T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

SE PRESENTAN DISPOSITIVO, PROCESO Y COMPOSICIONES PARA LA SEPARACION EFECTIVA DE CELULAS DE UNA MEZCLA DE CELULAS, EN EL CUAL PUEDE EMPLEARSE UNA SELECCION POSITIVA PARA SUMINISTRAR UNA POBLACION CELULAR DE INTERES. DE PARTICULAR UTILIDAD ES LA SEPARACION DE LAS CELULAS DE LAS CELULAS MONONUCLEARES DE LA SANGRE PERIFERICA, EN LA CUAL LOS MIEMBROS DE LAS LINEAS LINFOIDES O MIELOIDES PUEDEN AISLARSE Y USARSE PARA LA BUSQUEDA, LA DIAGNOSIS O LA TERAPIA. TAMBIEN ES DE INTERES LA SEPARACION CELULAR DE LA MEDULA DEL HUESO, DE LAS SUSPENSIONES TUMOLARES, DE LAS SUSPENSIONES DE TEJIDOS NINFOIDES, DONDE LAS CELULAS PUEDEN AISLARSE Y USARSE PARA UNA VARIEDAD DE PROPOSITOS. LAS CELULAS SEPARADAS PUEDEN SER HOMOGENEAS LIBRES DE AGENTES BIOLOGICOS EXOGENOS, CAPACES DE REPRODUCIRSE Y DE EXHIBIR SU COMPLETA ACTIVIDAD BIOLOGICA. FENOTIPOS MULTIPLES PUEDEN CAPTURARSE DE MANERA SIMULTANEA. LAS CELULAS CAPTURADAS PUEDEN ACTIVARSE ESPECIFICAMENTE CON CITOQUINAS Y ANTIGENOS PARA SUMINISTRAR CELULAS QUE TENGAN UN MHC RESTRINGIDO Y PRESENTEN FUNCIONES ESPECIFICAS DE ANTIGENO.
ES90307080T 1989-06-29 1990-06-28 Procedimiento para la captura y recuperacion de celulas. Expired - Lifetime ES2132063T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37409189A 1989-06-29 1989-06-29

Publications (1)

Publication Number Publication Date
ES2132063T3 true ES2132063T3 (es) 1999-08-16

Family

ID=23475243

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90307080T Expired - Lifetime ES2132063T3 (es) 1989-06-29 1990-06-28 Procedimiento para la captura y recuperacion de celulas.
ES95118035T Expired - Lifetime ES2173142T3 (es) 1989-06-29 1990-06-28 Dispositivo y procedimiento para la captura y recuperacion de celulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95118035T Expired - Lifetime ES2173142T3 (es) 1989-06-29 1990-06-28 Dispositivo y procedimiento para la captura y recuperacion de celulas.

Country Status (9)

Country Link
US (1) US6432653B1 (es)
EP (2) EP0701130B1 (es)
JP (1) JP2656988B2 (es)
AT (2) ATE179751T1 (es)
CA (2) CA1340565C (es)
DE (2) DE69033963T2 (es)
DK (2) DK0701130T3 (es)
ES (2) ES2132063T3 (es)
GR (1) GR3030533T3 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
JPH06506465A (ja) * 1991-04-05 1994-07-21 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ 細胞サブセットの欠落／陽性選択による免疫細胞の免疫療法活性の増強方法
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
CA2227327A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
AU5967100A (en) * 1999-07-21 2001-02-13 Britta Christensen A novel method for the improved isolation of a target cell population
DE10014708A1 (de) * 2000-03-24 2001-10-31 Walter Schubert Verfahren zur Identifizierung und Anreicherung von zellspezifischen Zielstrukturen
DE10014685B4 (de) * 2000-03-24 2004-07-01 Schubert, Walter, Dr. Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
US20070276352A1 (en) * 2002-06-04 2007-11-29 Stemcor Systems, Inc. Removable device and method for tissue disruption
AU2003240512B2 (en) * 2002-06-04 2009-11-05 The Board Of Trustees Of The Leland Stanford Junior University Device and method for rapid aspiration and collection of body tissue from within an enclosed body space
WO2004029221A2 (en) 2002-09-27 2004-04-08 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
WO2004042019A2 (en) * 2002-10-30 2004-05-21 Pointilliste, Inc. Systems for capture and analysis of biological particles and methods using the systems
DE10311981A1 (de) * 2003-03-12 2004-09-23 Oligene Gmbh Vorrichtung und Verfahren für den vivo-Zelltransfer
WO2005014801A1 (en) * 2003-08-04 2005-02-17 University Court Of The University Of Edinburgh Improvements in cell culture productivity
US7996825B2 (en) * 2003-10-31 2011-08-09 Hewlett-Packard Development Company, L.P. Cross-file inlining by using summaries and global worklist
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
JP2005336080A (ja) * 2004-05-26 2005-12-08 Asahi Kasei Medical Co Ltd 血管新生療法用細胞の分離回収方法および分離回収システム
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8691568B2 (en) * 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
PT2562268T (pt) 2008-09-20 2017-03-29 Univ Leland Stanford Junior Diagnóstico não invasivo de aneuploidia fetal por sequenciação
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
US20160178490A1 (en) * 2014-12-22 2016-06-23 Saint-Gobain Performance Plastics Corporation Capture system of cells and methods
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3397172A4 (en) 2016-02-01 2019-03-06 Regenmed Systems, Inc. CANNULA FOR TISSUE BREAKAGE
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1676579A (en) 1927-02-14 1928-07-10 Daniel Laurence Light-treatment process
US3016336A (en) 1957-09-30 1962-01-09 Fermco Lab Inc Deoxygenating method and product
US3645849A (en) 1969-04-17 1972-02-29 Gray Ind Inc Stability of enzymes
US3956219A (en) 1973-02-01 1976-05-11 Eli Lilly And Company Crosslinked polystyrene and substituted polystyrene compositions
IL43366A (en) 1973-10-04 1976-09-30 Yeda Res & Dev Production of organic reagents for the acylation of organic compounds
US4250139A (en) 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4464165A (en) 1980-11-24 1984-08-07 American Hoechst Corporation Material and method for removing immunoglobulins from whole blood
US4438198A (en) 1981-09-30 1984-03-20 Trimedyne, Inc. Biochemically active matrix for use in a bio-artificial organ
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4460445A (en) 1983-02-28 1984-07-17 Milliken Research Corporation Radiation-stable polyolefin compositions containing benzaldehyde acetals
DE3311889A1 (de) 1983-03-31 1984-10-11 Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach Verfahren zur irreversiblen bindung von protein an polystyroloberflaechen unter erhaltung der biologischen aktivitaet, so erhaltene polystyroloberflaechen und ihre verwendung
US4727027A (en) 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
US4620908A (en) 1983-10-03 1986-11-04 Biocell Laboratories, Inc. Method for destroying microbial contamination in protein materials
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4614513A (en) 1984-08-13 1986-09-30 Fred Hutchinson Cancer Research Center Method and apparatus for treatment to remove immunoreactive substances from blood
FR2582815B1 (fr) 1985-05-31 1989-04-07 Commissariat Energie Atomique Procede de separation des anticorps antifacteur viii : c, utilisable notamment pour l'epuration du plasma sanguin d'un hemophile de type a
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5081029A (en) 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
WO1987004628A1 (en) * 1986-01-30 1987-08-13 Fred Hutchinson Cancer Research Center Immunoselection method
SE459008B (sv) * 1986-09-04 1989-05-29 Bioinvent Int Ab Saett att framsstaella humana monoklonala antikroppar
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5241012A (en) 1987-05-19 1993-08-31 Applied Immune Sciences, Inc. Activated and conjugated polystyrene substrate
US5215926A (en) * 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
JP2639834B2 (ja) 1988-11-30 1997-08-13 有限会社ジオリサーチ 免疫記憶細胞懸濁液およびその調製方法
US4933410A (en) 1989-03-29 1990-06-12 Applied Immunesciences, Inc. Covalent attachment of macromolecules on substrate surfaces
US5081030A (en) * 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Also Published As

Publication number Publication date
DE69033963T2 (de) 2002-09-05
JP2656988B2 (ja) 1997-09-24
ATE179751T1 (de) 1999-05-15
EP0701130A3 (en) 1996-03-20
CA1337644C (en) 1995-11-28
EP0701130B1 (en) 2002-05-22
DK0405972T3 (da) 1999-11-01
EP0701130A2 (en) 1996-03-13
EP0405972A1 (en) 1991-01-02
ATE217974T1 (de) 2002-06-15
CA1340565C (en) 1999-05-25
EP0405972B1 (en) 1999-05-06
ES2173142T3 (es) 2002-10-16
US6432653B1 (en) 2002-08-13
DK0701130T3 (da) 2002-06-17
DE69033083T2 (de) 1999-08-26
GR3030533T3 (en) 1999-10-29
DE69033963D1 (de) 2002-06-27
JPH0339088A (ja) 1991-02-20
DE69033083D1 (de) 1999-06-10

Similar Documents

Publication Publication Date Title
ES2132063T3 (es) Procedimiento para la captura y recuperacion de celulas.
Jamieson et al. Generation of functional thymocytes in the human adult
Wright et al. Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells.
ATE449837T1 (de) Abstammungs-spezifische zellen und vorläuferzellen
Stern et al. Isolation and characterization of inflammatory cells from the human periapical granuloma
AU637702B2 (en) T-lymphocyte progenitor cell assay
FI92258B (fi) Onkostatiini-A:n käyttö diagnostisessa menetelmässä
CA2259984A1 (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
PT633930E (pt) Geracao in vitro de celulas dendriticas humanas e utilizacoes destas
ATE231912T1 (de) Zell/gewebekultursystem und -verfahren
ATE253112T1 (de) Menschliche hematopoietische stammzellen
ES2147720T3 (es) Factor de celulas madre.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
Glaser et al. In vitro generation of secondary cell-mediated cytotoxic response against a syngeneic Gross virus-induced lymphoma in rats
Altman et al. Natural cell-mediated cytotoxicity in guinea pigs: properties and specificity of natural killer cells
ES8402346A1 (es) Procedimiento para la obtencion de lineas de celulas animales y humanas cultivables permanentemente.
Hirschberg et al. Stimulation of human lymphocytes by allogeneic endothelial cells in vitro
Bagnasco et al. Clonal analysis of T lymphocytes infiltrating the thyroid gland in Hashimoto’s thyroiditis
Green et al. Phylogeny of immunocompetent cells: III. Mitogen response characteristics of lymphocyte subpopulations from normal and thymectomized frogs (Xenopus laevis)
Gibofsky et al. The identification of HL-A antigens on fresh and cultured human endothelial cells
SE8801426D0 (sv) Forfarande och medel for blodbehandling
Debout et al. Natural killer activity of Kurloff cells: a direct demonstration on purified Kurloff cell suspensions
Patel et al. Enrichment of mouse splenic natural killer cells using discontinuous polyvinylpyrrolidone silica (Percoll) gradients.
ATE73665T1 (de) Blutzellentrennung.
Lundgren et al. In vitro cytotoxicity by human lymphocytes from individuals immunized against histocompatibility antigens. II. Relation to HL-A incompatibility between effector and target cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 405972

Country of ref document: ES